Almirall SA operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Almirall SA with three other
pharmaceutical manufacturers in Europe:
Swedish Orphan Biovitrum AB (publ)
sales of 6.51 billion Swedish Kronor [US$726.22 million]
of which 100%
was Sales of Pharmaceuticals),
(617.54 million Euro [US$709.82 million]
of which 50%
was Non-Proprietary Homeopathic Medicines), and
based in the United Kingdom
(£570.50 million [US$748.69 million]
of which 38%
was Interventional Medicine).
Almirall SA reported sales of 639.38 million Euro (US$734.92 million)
December of 2017.
decrease of 16.4%
versus 2016, when the company's sales were 764.36 million Euro.
The sales level in 2017 was fairly close to the level five years ago: in 2012, Almirall SA had sales
of 682.88 million Euro.
Contributing to the drop in overall sales was the 59.4% decline
in Dermatology, from 203.39 million Euro to 82.66 million Euro.
There were also decreases in sales in
Licenses (down 12.2% to 79.83 million Euro)
However, these declines were partially offset by the increase in sales of
Own Network (Spain) (up 0.6% to 450.92 million Euro)
Corporate (up 18.3% to 25.97 million Euro)